Can You Take Simvastatin and Gemfibrozil Together?

No. The FDA classifies the combination of simvastatin and gemfibrozil as contraindicated, meaning the two drugs should not be used together. This is one of the highest-level safety warnings in drug labeling, indicating that the risks of combining these medications outweigh any potential benefit. If you are currently taking both, or if a healthcare provider has prescribed one while you are already on the other, you should speak with a pharmacist or physician immediately to discuss alternative treatment options.

What the Source Says

The FDA drug label for gemfibrozil directly states that "the concomitant administration of gemfibrozil with simvastatin is contraindicated." This language appears in both the drug interactions section and the contraindications section of the label, emphasizing the seriousness of the warning. The label also notes that both simvastatin and a related drug called repaglinide are substrates of a transporter protein called OATP1B1, and that combination therapy with gemfibrozil and either of these OATP1B1 substrates is contraindicated.

This is a documented, FDA-level directive, not a caution or warning to monitor closely. It is a directive to avoid the combination altogether.

How to Understand This

To understand why these two drugs are contraindicated, it helps to know what each one does and how they are handled by your body.

What simvastatin is: Simvastatin is a statin—a widely used class of medication that lowers cholesterol by blocking an enzyme in the liver called HMG-CoA reductase. Statins are among the most commonly prescribed medications for managing high cholesterol and reducing the risk of heart disease.

What gemfibrozil is: Gemfibrozil is a fibrate, a different class of lipid-lowering drug that works primarily by lowering triglycerides (another type of blood fat) and raising HDL cholesterol (the "good" cholesterol).

Why they interact: The source record does not specify the exact mechanism of the interaction. However, the label does identify that both simvastatin and repaglinide are substrates of a transporter protein called OATP1B1. This transporter is responsible for moving drugs into liver cells, where they are metabolized or eliminated. When gemfibrozil is present, it can interfere with this transporter, potentially reducing the clearance of simvastatin from the body and leading to higher-than-intended drug concentrations.

General background on statin and fibrate safety: Both statins and fibrates can affect muscle and liver function, and both classes carry a small risk of muscle injury (myopathy) or, rarely, severe muscle breakdown (rhabdomyolysis). When used alone and at appropriate doses, these risks are generally low and manageable with monitoring. However, combining a statin with a fibrate increases the overall burden on the body's ability to handle these drugs and raises the risk profile significantly. This is why healthcare providers often avoid combining them, and why the FDA has moved to contraindicate the pairing entirely in the case of simvastatin and gemfibrozil.

Other statins may have different guidance: It is important to note that the contraindication applies specifically to simvastatin and gemfibrozil. Some other statin and fibrate combinations may have different levels of restriction or may be used together with careful monitoring. This underscores why it is critical to discuss your specific medications with a pharmacist or physician rather than assuming all statins behave the same way with all fibrates.

Who Should Pay Particular Attention

The contraindication applies to all patients taking simvastatin. There are no age groups, kidney function categories, or other conditions that make this combination acceptable. If you are taking both medications, the issue applies to you, regardless of your other health conditions, how long you have been on the drugs, or whether you feel fine.

However, certain patients may have additional considerations worth discussing:

• Patients with a history of muscle pain or weakness on statins: If you have experienced myalgia (muscle pain) or other muscle symptoms on a statin in the past, this history makes the safety of drug interactions even more important to understand and avoid.
• Patients with kidney or liver disease: The liver and kidneys play major roles in removing these drugs from the body. If your liver or kidney function is reduced, any interaction that slows drug clearance becomes more serious.
• Patients on multiple cholesterol or triglyceride medications: If you need to lower both cholesterol and triglycerides, you may be looking at combination therapy, but simvastatin plus gemfibrozil is not a safe option. Your pharmacist or doctor can discuss other combinations or individual agents.

A Hypothetical Example

Consider a patient with high cholesterol and elevated triglycerides who is already taking simvastatin 20 mg daily for cholesterol control. A new physician, unaware of the existing simvastatin, prescribes gemfibrozil 600 mg twice daily to address the high triglycerides. If both medications are filled and taken as prescribed, the patient could develop accumulation of simvastatin in the bloodstream due to the OATP1B1 transporter interference. Over days or weeks, this could lead to elevated simvastatin levels, increasing the risk of muscle injury or liver problems—even though the patient was not intentionally exposed to a dangerous drug overdose and was following both prescriptions as written. This scenario illustrates why pharmacies maintain drug-interaction screening systems and why it is essential for all providers and pharmacies involved in your care to have a current, complete list of everything you are taking.

What to Discuss With a Pharmacist or Physician

If you are currently on both simvastatin and gemfibrozil, or if one has just been prescribed while you are on the other, bring this up at your next appointment or call your pharmacist right away. Here are some conversation starters:

• "I've seen that simvastatin and gemfibrozil are contraindicated together. Can we review my medications and discuss alternatives?" This opens the discussion and signals that you are aware of the concern.
• "Which medication is more important for my condition right now—the cholesterol medication or the triglyceride medication?" Sometimes one drug is more critical to your health plan than the other, and knowing that helps your provider prioritize.
• "Are there other statins that are safer with gemfibrozil, or other fibrates that work with my current statin?" This frames the question in terms of finding a safer combination rather than abandoning your treatment plan.
• "If I need to stop one medication, how should I do that—should I taper it, or stop right away?" Stopping a cholesterol-lowering medication abruptly can sometimes carry its own risks, so ask for specific guidance rather than guessing.
• "Are there other ways to manage my triglycerides if I cannot take gemfibrozil with my statin?" Triglycerides can often be managed through diet, exercise, weight loss, and alcohol reduction; some patients may also benefit from fish-oil supplements or other medications.

Do not stop or change your medications on your own based on this information. Always work with your healthcare team to make safe, informed decisions about your treatment.

Key Takeaways

• Simvastatin and gemfibrozil are classified as contraindicated by the FDA—they should not be taken together.
• The contraindication is stated directly in the FDA drug label for gemfibrozil and applies to all patients, regardless of age, kidney function, or other conditions.
• The source record does not specify the exact mechanism, but both drugs interact with the OATP1B1 liver transporter, and gemfibrozil can interfere with the clearance of simvastatin.
• If you are taking both medications, contact your pharmacist or doctor immediately to discuss stopping one and exploring safer alternatives.
• Other statin and fibrate combinations may have different safety profiles; never assume that switching to a different statin will make the combination safe without checking with a pharmacist.

Sources

• DailyMed: FDA Drug Labeling Database — Search for the gemfibrozil label to view the contraindications and drug interactions sections directly.
• NIH/NLM RxNorm — Reference database for drug names, strengths, and identifiers.
• FDA Open Data Portal — Access to FDA drug labeling and adverse event data.

If you are taking simvastatin, gemfibrozil, or any combination of cholesterol and triglyceride medications, use checkdruginteractions.com to check for documented interactions with other drugs in your regimen. Always confirm any medication changes, combinations, or discontinuations with your pharmacist or physician before acting on them.